Impact of ABCB1 single-nucleotide polymorphisms on treatment outcomes with salmeterol/fluticasone combination therapy for stable chronic obstructive pulmonary disease.
OBJECTIVE
To investigate the relationship between ABCB1 single-nucleotide polymorphisms and the efficacy of salmeterol/fluticasone combination (SFC) inhalation therapy for stable chronic obstructive pulmonary disease (COPD) in a Chinese Han population.


METHODS
A total of 362 patients with stable COPD were recruited between July 2012 and March 2014. Based on the therapeutic effects of lung function improvement and COPD Assessment Test (CAT) scores, all patients were either placed into the effective group (n = 138) or the ineffective group (n = 224). Three common polymorphisms (rs1045642C > T, rs1128503C > T, and rs1202184A > G) in the ABCB1 gene were analyzed by polymerase chain reaction-restriction fragment length polymorphism in these patients. All data were analyzed by SPSS version 18.0 software.


RESULTS
The genotype and allele frequencies of the ABCB1 rs1045642C > T polymorphic locus were significantly different between the effective group and the ineffective group under the codominant, recessive, and allele models (all p < 0.05). Haplotype analysis of ABCB1 indicated that CTA (rs1045642C-rs1128503T-rs1202184A) haplotype frequencies in the effective group were significantly lower than the ineffective group (p = 0.022), but TCG (rs1045642T-rs1128503C-rs1202184G) haplotype frequencies in the effective group were significantly higher than the ineffective group (p = 0.048). Logistic regression analysis showed that smoking history and rs1045642 CT + CC/TT may be correlated with the efficacy of SFC inhalation therapy in stable COPD patients.


CONCLUSIONS
ABCB1 rs1045642C > T polymorphism and CTA/TCG haplotypes, as well as smoking history may influence the efficacy of SFC inhalation therapy in stable COPD patients in the Chinese Han population.
1 Department of Respiratory Diseases, Hubei Zhongshan Hospital , Wuhan, People's Republic of China .
Xin-Wei
XW
Wang
2 Department of Internal Medicine, Wuhan Institute of Tuberculosis Prevention , Wuhan, People's Republic of China .
Yan-Lin
YL
Zhang
3 Department of Laboratory, Wuhan Union Hospital , Wuhan, People's Republic of China .
Ying
Y
Xiong
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000235:genetics; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D002681:China; D005260:Female; D000068297:Fluticasone-Salmeterol Drug Combination / Q000627:therapeutic use*; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000235:genetics*; D016896:Treatment Outcome
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D000068297:Fluticasone-Salmeterol Drug Combination